AI assistant
Ambu Share Issue/Capital Change 2018
3353_rns_2018-11-21_ee531ab0-1b47-4c4b-ad5c-ab4177904dbf.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Ambu
Ideas that work for life
Capital increase in connection with exercise of warrants
In December 2015, Ambu A/S issued 770,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 46 individuals participate in the 2015 scheme. The vesting period is three years and can therefore be exercised in the trading window that opened on 13 November 2018 in connection with Ambu's Annual report for 2017/18.
Since 13 November 2018, instructions have been received to exercise warrants as follows:
- 2015 scheme: Four individuals have issued instructions to exercise a total of 105,000 warrants at the agreed exercise price of DKK 39.26 per share with a nominal value of DKK 0.50.
Today Ambu's Board of Directors decided to carry out the capital increase relating to the exercised warrants.
As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 52,500 from DKK 125,637,300 to DKK 125,689,800 through the issue of 105,000 Class B shares.
Following this and in consideration of the employees having left the company, there are 650,000 remaining warrants under the 2015 scheme being held by 39 individuals.
The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 27 November 2018 under the ISIN code of Ambu A/S' existing B shares (DK0060946788).
Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.
| Number of shares (nominal value DKK 0.50) | Nominal value (DKK) | Voting rights | |
|---|---|---|---|
| A shares | 34,320,000 | 17,160,000 | 343,200,000 |
| B shares | 217,059,600 | 108,529,800 | 217,059,600 |
| Total | 251,379,600 | 125,689,800 | 560,259,600 |
Ambu
Company announcement no. 3 2018/19
21 November 2018
Ambu
ideas that work for life
Contact
Lars Marcher, President & CEO, tel. +45 5136 2490, email: [email protected]
Ambu A/S
Baltorpbakken 13
2750 Ballerup, Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.ambu.com
About Ambu
Since 1937, breakthrough ideas have fuelled our work on bringing efficient healthcare solutions to life. This is what we create within our fields of excellence – Visualisation, Anaesthesia, and Patient Monitoring & Diagnostics. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of our products. We are dedicated to improve patient safety and determined to advance single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to our newest landmark solutions like the Ambu aScope™ – the world's first single-use flexible endoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognized medtech companies in the world. Headquartered near Copenhagen in Denmark, Ambu employs approximately 2,700 people in Europe, North America and the Asia Pacific. For more information, please visit www.ambu.com.
Ambu
Company announcement no. 3 2018/19
21 November 2018
Page 2 of 2